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Abstract
Background
The presence of deletions can complicate genetic diagnosis of autosomal reces-
sive disease.
Method
The DNA of patients was analyzed in a diagnostic setting.
Results
We present three unrelated patients each carrying deletions that encompass the
37 kb CLN8 gene and discuss their phenotype. Two of the cases were hemizy-
gous for a mutant allele – their deletions unmasked a mutation in CLN8 on the
other chromosome.
Conclusion
Microarray analysis is recommended in any patient suspected of NCL who is
apparently homozygous for a mutation that is not present in one of the parents
or when the family has no known consanguinity.
Introduction
The neuronal ceroid lipofuscinoses are a group of progressive
neurodegenerative disorders that mainly, but not exclusively,
affect children. Mutations in 13 genes have been reported,
with some cases still remaining genetically undiagnosed. Most
are inherited as autosomal recessive. The type of mutation
affects the age of onset of disease as well as its severity.
A gene-based nomenclature is increasingly being used
(Williams and Mole 2012). Over 440 mutations have been
reported in the NCLs and these are collected in the freely
accessible NCL mutation database (www.ucl.ac.uk/ncl/).
Some NCL genes carry mutations that are shared across a
population or even across continents, but many mutations are
unique to one or a few families. In our research and diagnostic
work that has screened over 900 patients for mutations in
NCL genes over the last 10 years, we noticed several cases car-
ried large genomic deletions that encompassed the CLN8 gene
(OMIM *607837), which we report here. The presence of dele-
tions can complicate genetic diagnosis. One Irish patient has
already been reported with a de novo terminal deletion of the
short arm of chromosome 8p23.3 (Allen et al. 2012). One
Turkish family carries a 2.6 kb intragenic deletion in CLN8
that causes more severe disease than most other mutations
(Reinhardt et al. 2010). To date, ~30 other mutations that
cause CLN8 disease have been reported, of which 21 are mis-
sense mutations, one is a nonsense mutation, and five are small
deletions of 1–3 bp. CLN8 disease is seen in many countries.
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CLN8 belongs to the TLC superfamily that shares a 200
amino acid domain (amino acids 62–262) encompassing
five transmembrane helices (Winter and Ponting 2002).
Mutations that affect this domain tend to result in a sev-
ere phenotype typical of variant late infantile NCL pre-
sumably due to complete loss of function and even
protein location (Kousi et al. 2012), although the mis-
sense mutation p.(Gln194Arg) is present in a patient with
a slightly more severe disease course (Cannelli et al.
2006), and affected siblings with p.(Gln256Glu) have a
noticeably varying disease course (Zelnik et al. 2007).
Missense mutations that lie outside this domain, such as
p.(Arg24Gly) can result in a much less severe phenotype
such as Progressive Epilepsy with Mental Retardation
(EPMR or Northern Epilepsy), first described in Finland
(Hirvasniemi et al. 1994; Ranta et al. 1999). Most other
missense mutations cause similar disease, although
p.(Trp263Cys) is associated with a later age of onset and
more protracted disease course (Kousi et al. 2012).
Here, we present three unrelated patients each carrying
deletions that encompass the 37 kb CLN8 gene, and dis-
cuss their phenotype. Two of the cases were hemizygous
for a mutant allele – their deletions unmasked a mutation
in CLN8 on the other chromosome. We now recommend
including microarray analysis in any patient suspected of
NCL who is apparently homozygous for a mutation that
is not present in one of the parents or when the family
has no known consanguinity.
Material and Methods
Identification of subjects
One family was part of a research-directed approach to
identify the underlying disease genes in families diagnosed
with NCL and contained within the DNA database at
UCL. Blood from two further families suspected of NCL
were received by the Regional Genetics Laboratory at
Great Ormond Street Hospital for diagnostic testing.
Ethical compliance
The participation of all families was possible by their
informed consent and all procedures employed were
reviewed and approved by the appropriate institutional
review committee.
Illumina SNP beadchip analysis
To assess the presence of large structural variants or large
regions of homozygosity (>1 Mb) in family A, the DNA
sample was run on HumanOmniExpress BeadChips as
per the manufacturer’s instructions (Illumina Inc). Data
were visualized and analyzed using the GenomeStudio
Data Analysis Software (Illumina Inc., San Diego, CA,
USA).
DNA and mutation analysis
Genomic DNA was obtained from all subjects using stan-
dard procedures. All of the coding exons and intron/exon
boundaries of the CLN8 gene (NM_001042432.1) were
amplified by PCR (primer sequences available on request)
using Megamix (Microzone, Haywards Heath, UK). PCR
products were purified with AmpureXP (Beckman Coul-
ter, High Wycombe, UK) and then Sanger sequenced
using BigDye Terminator v.3.1 technology (Life Tech-
nologies, Paisley, UK). Mutation Surveyor software
(SoftGenetics, State College, PA, USA) was used to align
traces to the reference sequence and call the variants/mu-
tations. Alamut software (Interactive Biosoftware, Rouen,
France) was used to investigate the potential pathogenic-
ity of the variants by in silico software tools, for example,
PolyPhen, SIFT, SNPs. Genome-wide array CGH analysis
for Family B was carried out using the NimbleGen 135k
CGH microarray (Roche NimbleGen, Madison, WI,
USA), scanned using GenePix Pro 7 (Molecular Devices,
Sunnyvale, CA, USA), and processed using Infoquant
Fusion software (Infoquant, London, UK).
Results
Child A (UCL303 Pa)
This family is from Argentina with no known consanguin-
ity. The proband was 5 years old at time of blood collec-
tion, with one elder sibling who died at the age of 13 years
with the same disease, one elder sibling who was unaffected,
and a younger sibling whose disease status was unknown.
She experienced seizures from 3 years and 8 months; ataxia
from 4 years; myoclonus from 3 years 6 months; drop
attacks from 4 years and neuro-regression from 4 years of
age; The visual evoked potential (VEP) was abnormal at
5 years; somatosensory evoked potential (SSEP) was said to
be normal at 5 years. No further clinical details are avail-
able. Electron microscopy showed curvilinear inclusions
(CL) in skin biopsy. Brain imaging showed cortical and
cerebellar atrophy. These investigations confirmed a diag-
nosis of NCL but the underlying gene was not known.
Whole genome genotyping revealed a large homozy-
gous deletion of 378.6 kb on 8p23 that encompassed the
CLN8 gene as well as three other genes (Fig. 1).
Child B
The proband from this British family had normal devel-
opment with some mild language delay until the age of
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4 years. From then onwards, her parents became con-
cerned about worsening gait unsteadiness, loss of ability
to climb stairs, and increasing difficulties with fine motor
tasks. She experienced her first seizures at 4 years,
6 months, characterized by sudden falls lasting for sec-
onds. On review at 4 years 8 months, she was showing
myoclonic seizures, an ataxic gait, loss of fine motor
skills, coordination difficulties, and visual impairment.
The disease has been rapidly progressive with loss of inde-
pendent ambulation and expressive language skills, and
development of dysphagia requiring feeding support
within 1 year of diagnosis. At 8 years of age, she was fully
dependent on carers for all her needs. She died at 9 years
and 2 months old.
Microscopy of a blood film showed no vacuolated lym-
phocytes. Electron microscopy of lymphocytes showed
occasional lymphocytes containing membrane-bound,
electron-dense, lipo-protein storage material with a fin-
gerprint profile (FP) suggestive of a variant form of NCL.
Array-CGH analysis (resolution of ~0.2 Mb) revealed a
copy number loss (~54 kb) at 8p23.3 that encompasses
the CLN8 gene (Fig. 2). This copy number loss was too
small to be confirmed by fluorescent in situ hybridization
(FISH), and quantitative PCR was not validated in our
laboratory at the time of detection. In addition, a MLPA
dosage kit was also not available at that time. Therefore,
we were unable to confirm the copy number loss by
another method. However, microarray analysis in the
father confirmed that he is a carrier of the same copy
number loss, so the fact that it was inherited by the pro-
band indicated that it was highly unlikely to be a false
positive. Sequence analysis of CLN8 indicated that the
proband was also “hemizygous” for a novel variant
c.728T>C p.(Leu243Pro). Leucine and proline have a
moderate physicochemical difference and the leucine at
residue 243 is conserved in 6/8 species. The proline resi-
due is predicted not to be tolerated at this position and
the amino acid change is predicted to be possibly damag-
ing by in silico software. It is therefore considered likely
to be pathogenic. Analysis of parental samples confirmed
that the mother is a carrier of the c.728T>C variant.
Together, these data confirm that the proband is a com-
pound heterozygote for the 54 kb deletion and the
c.728T>C variant.
Child C
This male child is from a nonconsanguineous British fam-
ily. There were no developmental concerns until the onset
of a progressive visual impairment from 3 years
8 months, and features consistent with a retinal dystro-
phy. At 4 years of age, he was neurologically normal aside
from the severe visual impairment with no evidence of
seizures or cognitive decline. Brain imaging showed white
matter abnormalities and he was initially investigated for
a progressive leukodystrophy. He developed possible sei-
zures at the age of 4 years 9 months and was started on
medication following the EEG finding of abnormally slow
Figure 1. Results for chromosome 8 from whole genome genotyping represented by the log ratio in the bottom and B allele frequencies on the
top panels. The green vertical bar indicates the location of CLN8 in chromosome 8. A large homozygous deletion on 8p23.3 encompassing CLN8
can be identified in Child A by the abrupt decline in the log ratio accompanied by randomly placed markers in the B allele frequency showing no
specific hybridization with any probe in the array (Reference sequence: NM_001042432.1).
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Figure 2. The upper panel is the array CGH result showing the heterozygous copy number loss of ~54 kb at 8p.23.3, which encompasses the
CLN8 gene (circled in red). The lower panel shows the Sanger sequencing results for the “hemizygous” c.728T>C, p.(Leu243Pro) novel variant in
Child C. Upper and lower panels are the normal sequence (forward & reverse) and the middle panels are the patient (forward and reverse)
(Reference sequence: NM_001042432.1).
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background activity and runs of epileptiform discharges.
By 5 years and 2 months of age, he had a marked Parkin-
sonian movement disorder with difficulties initiating
movements and a shuffling gait. Seizures were well con-
trolled. Anti-Parkinsonian treatment was considered but
within 6 months, he had lost all independent ambulation,
speech, play, and feeding skills. A gastrostomy was placed.
By 7 years of age, he was completely dependent for all his
needs. He has prolonged episodes of restless and distress-
ing hyperkinetic limb movements which have only par-
tially responded to medication.
Microscopy of a blood film showed no vacuolated lym-
phocytes but electron microscopy showed approximately
8% of lymphocytes containing membrane-bound, elec-
tron-dense, lipo-protein material with a fingerprint pro-
file, suggestive of a variant form of NCL. All four genes
associated with vNCL, CLN5, CLN6, CLN7/MFSD8, and
CLN8, were Sanger sequenced and he was apparently
homozygous for the c.763C>T, p.(Gln255*) nonsense
mutation of CLN8 (Fig. 3). However, parental studies
showed that the father was a carrier of the c.763C>T
mutation, but the mother was not. Subsequent microarray
analysis showed that the proband was heterozygous for a
235 kb deletion in 8p23.3, which encompassed the CLN8
gene, and was maternally inherited.
Discussion
Our study of these families revealed three new genomic
deletions that encompassed the CLN8 gene. In one family,
this was present on both disease alleles. In two families,
their deletions unmasked two novel point mutations. The
family with the largest deletion (Family A) had an inter-
esting phenotype which may be due to the loss of addi-
tional nearby genes. Microscopically visible distal 8p
deletions are known to be associated with growth and
mental impairment, minor facial anomalies, congenital
heart defects, and behavioral problems – these are features
of Cornelia de Lange syndrome (OMIM #122470). How-
ever, although the clinical phenotypes of these cases show
variability, this is within that previously described for late
infantile onset CLN8 disease (Aiello et al. 2011)
(Table 1).
For patients with neurodevelopmental disorders and
any form of intellectual disability, microarray analysis has
superceded karyotype analysis as the first-line test in the
majority of diagnostic laboratories, due to its increased
sensitivity in detecting copy number variants (CNVs).
Although whole exome sequencing (WES) and targeted
gene panels are becoming much more widespread, there
are still currently significant limitations in detecting CNVs
Figure 3. Sanger sequencing results for Child C showing the “hemizygous” c.763C>T, p.(Gln255*) mutation. Top and bottom panels are the
normal sequence (forward and reverse) and the middle panels are the patient (forward and reverse) (Reference sequence: NM_001042432.1).
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and trinucleotide repeats, due to a high level of biases
and artifacts. However, as both sequencing technologies
and bioinformatics improve, these limitations may
become less of an issue.
This analysis contributes to establishing the prevalence
of deletions at 8p23.3 and adds to the spectrum of CLN8
mutations. We now recommend including microarray
analysis in any patient suspected of NCL who is appar-
ently homozygous for a mutation that is not present in
one of the parents or when the family has no known con-
sanguinity.
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